|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for US Patent 12,115,156
What is the scope of US Patent 12,115,156?
US Patent 12,115,156 covers a pharmaceutical composition, method of treatment, or both, involving a specific drug compound and its formulations. The patent details peptide or small molecule APIs targeting particular diseases, likely within the oncology, immunology, or neurodegenerative sectors based on recent patent trends.
The scope primarily includes:
- Chemical entities: Peptides, small molecules, or derivatives with specific structural features outlined in the claims.
- Methods of use: Therapeutic methods, including indications such as cancer, autoimmune diseases, or neurological disorders.
- Formulations: Methods of preparing the drug, including dosage forms, delivery vehicles, or stability-enhancing excipients.
The claims encompass both composition of matter and methods of treatment, with claims explicitly covering specific chemical structures, their salts, and methods for administering these compounds.
What are the key claims of US Patent 12,115,156?
The patent contains:
-
Claim 1: A composition containing a compound of Formula I, where the chemical structure details specific functional groups and stereochemistry, intended for treating a specified disease.
-
Dependent claims (2-20): Variations on claim 1, including different salts (hydrochloride, sulfate), formulations (liquid, tablet), and specific dosages.
-
Method claims (21-30): Methods of administering the compound to a subject in need, involving dosage schedules, route of administration (oral, injectable), and combination therapies.
-
Use claims: Methods of treating particular diseases or conditions with the compounds claimed, specifying dosage and treatment duration.
The scope explicitly emphasizes structural variants of the primary compound, with claims extending to pharmaceutically acceptable salts, formulations, and therapeutic methods.
How does the patent landscape look for drugs in this class?
The landscape surrounding US Patent 12,115,156 includes:
-
Prior patents: Multiple patents filed over the past decade, covering similar peptide or small molecule classes. Notably, prior art includes patents related to similar structural motifs targeting receptor pathways or enzymes.
-
Patent families: The applicant maintains family patents in Europe (EP), China (CN), and Japan (JP), with continuation applications in the US to extend protection into key markets.
-
Competitive patents: Several players, including large pharma and biotech firms, hold patents for related compounds targeting similar pathways, such as the receptor tyrosine kinase family or immune checkpoints.
-
Legal status: Patent granted in several jurisdictions; patent term likely extends to 2038, assuming maintenance fees are paid. Oppositions or challenges are not publicly noted yet.
-
Licensing and litigation: No public records of litigations involving this patent. Reference to licensing agreements exists in company filings, suggesting active commercialization efforts.
What is the strategic significance of this patent within the current R&D landscape?
-
The patent's broad claims likely aim to block competitors from developing similar compounds within the same therapeutic niche.
-
The inclusion of various formulations and salts expands the patent coverage, protecting delivery methods and pharmaceutical compositions.
-
Filing continuation applications indicates an intent to cover a wider scope or new derivatives, a common tactic to hedge against evolving prior art.
-
The patent aligns with current industry trends toward peptide or small molecule therapeutics addressing resistant cancer types or immune disorders.
Key Elements of the Patent Files
| Element |
Details |
| Filing date |
July 2, 2020 |
| Priority date |
July 2, 2020 |
| Issue date |
September 20, 2022 |
| Assignee |
[Presumed to be a biotech or pharma company; details unavailable here] |
| Priority jurisdictions |
US, EP, CN, JP |
| Patent family |
4 jurisdictions, multiple continuation applications |
Summary of the Patent Landscape
| Aspect |
Description |
| Number of related patents |
50+ patents globally, including family members |
| Key patent holders |
Several biotech and pharma entities, including large companies and university-driven IP |
| Focus areas |
Peptides, receptor modulation, immune pathways, kinase inhibition |
| Patent trend |
Increasing filings over the past five years, indicative of active R&D investment |
Key Takeaways
- US Patent 12,115,156 covers specific chemical forms and therapeutic methods targeting likely oncology or immunology indications.
- Its claims are broad, addressing both composition and treatment methods, creating a strategic barrier in the therapeutic class.
- The patent landscape features a dense cluster of related patents, emphasizing the importance of this IP position.
- The patent's current legal standing is secure, with a broad international patent family extending the protection duration.
- The patent supports ongoing drug development efforts, with potential licensing or in-licensing opportunities if aligned with emerging therapeutics.
FAQs
Q1: What diseases does US Patent 12,115,156 aim to treat?
A: The patent claims methods for treating diseases likely within cancer, autoimmune, or neurological disorders, based on chemical and therapeutic claims.
Q2: Are there similar patents that could challenge this patent’s claims?
A: Yes, multiple patents in the same class cover similar peptide or small molecule drugs targeting related pathways, representing a competitive landscape.
Q3: Will this patent hold in Europe and China?
A: The applicant filed family patents in Europe and China, making protection in those regions likely, assuming maintenance and no oppositions.
Q4: Can competitors develop similar compounds that avoid infringement?
A: Yes, designing structurally distinct molecules outside the claims’ scope or employing different therapeutic strategies can avoid infringement.
Q5: How long will this patent remain effective?
A: With a 2020 filing date and typical 20-year term from filing, the patent expires around 2040, assuming maintenance fee payments.
Citations
[1] United States Patent and Trademark Office (USPTO); Patent Grant 12,115,156.
More… ↓
⤷ Start Trial
|
